 |
In October 2022 Avacta completed the acquisition of the largest independent UK-based IVD distributor, Launch Diagnostics, which has provided the group with well-established sales channels in the professional, centralised hospital laboratory testing market in the UK, Ireland and France.
Launch Diagnostics has over 30 years’ track record and is headquartered in Kent. It supplies a diverse portfolio of innovative, high-quality devices and equipment that diagnose disease, providing complete solutions from diagnostic tests to equipment, servicing, training and technical support. |
 |
In May 2023 Avacta completed the acquisition of Belgian diagnostics business Coris BioConcept, which specialises in developing, manufacturing and marketing rapid diagnostic kits for the detection of human respiratory, gastro-enteric and blood-borne pathogens (bacteria, viruses and parasites) and for the detection of antibiotic resistance markers (RESIST range). These tests are based on the lateral flow immunochromatography technology with colloidal gold particles or latex microspheres and are CE marked for professional use.
Coris, which is ISO13485 certified, also provides services for custom test development and contract manufacturing. The company, which was founded in 1996, is present in more than 80 countries in Europe, Asia, South America, Africa and Oceania. |
 |
The Affimer® platform is Avacta’s proprietary alternative to antibodies with significant technical and commercial benefits to differentiate lateral flow tests and other immunodiagnostic products through improved performance compared with antibody-based tests. Affimer® reagents are ideal tools for use in diagnostic test development due to being highly specific, reproducible, stable, and easy to manufacture at scale. |